Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2001-1326
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres ; volume:6 ; number:1 ; day:3 ; month:11 ; year:2017 ; pages:1-9 ; date:12.2017
Clinical and translational medicine ; 6, Heft 1 (3.11.2017), 1-9, 12.2017
- Creator
-
Toellner, Hannah
- Contributor
-
Hughes, G.
Beswick, W.
Crooks, M. G.
Donaldson, C.
Forrest, I.
Hart, S. P.
Leonard, C.
Major, M.
Simpson, A. J.
Chaudhuri, N.
SpringerLink (Online service)
- DOI
-
10.1186/s40169-017-0172-3
- URN
-
urn:nbn:de:101:1-2018090514572500552471
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Toellner, Hannah
- Hughes, G.
- Beswick, W.
- Crooks, M. G.
- Donaldson, C.
- Forrest, I.
- Hart, S. P.
- Leonard, C.
- Major, M.
- Simpson, A. J.
- Chaudhuri, N.
- SpringerLink (Online service)
Other Objects (12)
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Factors influencing the uptake of neonatal bereavement support services – Findings from two tertiary neonatal centres in the UK
Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres
Nintedanib-Induced Renal Thrombotic Microangiopathy
Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Factors influencing the uptake of neonatal bereavement support services – Findings from two tertiary neonatal centres in the UK
Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres
Nintedanib-Induced Renal Thrombotic Microangiopathy
Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Factors influencing the uptake of neonatal bereavement support services – Findings from two tertiary neonatal centres in the UK
Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres
Nintedanib-Induced Renal Thrombotic Microangiopathy